Physician profile
Bashar Maskoni
NPI 1942733944
$145.35
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $94.27 · 2021: $25.52 · 2022: $25.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $28.79 | 2020 | |
| Vanda Pharmaceuticals INC. | $26.09 | 2020 | |
| Glaxosmithkline, LLC. | $25.56 | 2022 | |
| Lilly USA, LLC | $25.52 | 2021 | |
| Merck Sharp & Dohme LLC | $13.76 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $13.45 | 2020 | |
| Novo Nordisk INC | $12.18 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Maskoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.